Cardio ThinkLab

ESC Recommendation: High sensitivity troponin assay vs conventional assay

Advantages of hs-cTn Assays Over Conventional Assays

Compared to conventional assays, hs-cTn assays are associated with the advantages below:1

Higher sensitivity for detection of MI at presentation

Higher negative predictive value for AMI

Shorter interval between 2 cTn measurements

Can detect patients whose cTn was undetectable using conventional assays

Value of High-Sensitive Cardiac Troponin2

Early detection of MI

Enables more rapid “rule-in” and “rule-out” of MI

Increase detection of type 1 MI and type II MI

Decrease diagnosis of unstable angina

Higher accuracy at the exact low cost

A Quantitative Marker for Cardiomyocyte Damage

hs-cTn assays can detect cardiac troponin in a significant portion of healthy population.1

Apart from MI, there are several other conditions that can be associated with increased cTn levels.1

Conditions Other Than Acute Type 1 MI Associated with Myocardial Injury Causing cTn Elevations1

Tachyarrhythmias, heart failure, hypertensive emergencies, critical illness, myocarditis, Takotsubo syndrome, valvular heart disease, aortic dissection and pulmonary embolism

In elderly patients with renal dysfunction, chronic coronary syndromes or hypertensive heart disease are the most frequent causes of elevated cardiac troponin concentration

Assessing the rise and/or fall of cTn levels can help differentiate MI from other conditions associated with cardiomyocyte injury1,3

High Throughput Laboratory Assays vs. POCT

Cardiac troponin assays that are run on automated platforms are mostly sensitive or high-sensitivity assays.1

Most of the POCTs in current use are not considered sensitive or high-sensitivity assays.
Automated assays are preferred.1

ESC 2020 does not recommend the use of biomarkers such as CK, CK-MB, h-FABP, or copeptin, in addition to hs-cTn.1

Updates from Leading Experts

STRONG-HF: Post-discharge Heart Failure Management and Implementation of GDMT Heart Failure Therapy

Prof Alexandre Mebazaa shares the key results and highlights from the STRONG-HF study that assessed the safety, tolerability of optimization of guideline directed medical therapy. [...]


CANVAS study: NT-proBNP and CVD risk reduction

Can you give us a short description of the CANVAS program? The CANVAS program was a set of two trials, whose goal was to evaluate the role of an SGLT2...

1 July 2021
Dr James L Januzzi